The CCDC102A Knockout Jurkat Polyclonal Cells product comprises a population of Jurkat T lymphocytes that have undergone CRISPR/Cas9-mediated disruption of the CCDC102A gene, generating a polyclonal knockout pool suitable for studying the loss-of-function effects of this poorly characterized coiled-coil domain protein. This polyclonal knockout cell population provides a genetically heterogeneous loss-of-function model that reflects the natural variance of CRISPR editing, enabling robust functional genomics investigations without clonal selection bias.
The Jurkat cell line is an immortalized human T lymphocyte leukemia line originally derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. These suspension cells are extensively employed in immunology and cancer research to dissect T cell receptor (TCR) signaling, apoptosis, and HIV infection mechanisms. Their well-characterized signaling pathways and ease of culture make Jurkat cells an ideal host for studying gene function in T cell biology.
CCDC102A encodes a protein containing coiled-coil domains, a structural motif often mediating protein-protein interactions. Although its precise molecular functions remain unclear, bioinformatic predictions suggest potential involvement in centrosomal organization and interactions with centrosomal proteins. The mechanistic role of CCDC102A is not well defined; it may contribute to cytoskeletal dynamics, but upstream regulators, downstream targets, and representative pathway components have yet to be characterized. Thus, knockout models are essential for elucidating its biological significance.
In the Jurkat T cell context, disruption of CCDC102A offers a unique opportunity to investigate how this centrosomal-associated protein influences T cell functions such as TCR signaling, proliferation, apoptosis, and cytokine secretion. Given the importance of centrosomes in cell division and polarity, this model may reveal CCDC102A??s impact on T cell activation and migration, processes crucial for immune responses and leukemia pathogenesis. The polyclonal nature ensures that a range of editing outcomes are represented, mirroring the diversity of potential in vivo loss-of-function scenarios.
Researchers can employ these polyclonal knockout cells in a variety of downstream assays, including Western blotting and RT-qPCR to confirm gene disruption and assess expression changes, flow cytometry to analyze surface markers and signaling phosphoproteins, apoptosis and proliferation assays to evaluate cell fate decisions, cytokine secretion analysis to measure functional T cell responses, reporter assays for TCR signaling, and migration assays to study cytoskeletal-dependent movement. This product is well-suited for functional genomics, drug target validation, and cancer research applications. For further information or technical support, please contact Ascent Research.
